This is a working overview of aseptic technique, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-22 and is reviewed periodically as new material appears.
Shipping and short-term transfer require attention to temperature control and physical stability. Frozen solutions are commonly sent on dry ice, while lyophilized powders may travel with gel packs or insulated packaging. Thawing should be done slowly on ice or in a refrigerator, not by vigorous heating, and the solution should be mixed gently before use. Temperature loggers can document excursions during transit, but their presence does not prove that a peptide remained stable. Analytical checks such as chromatography or mass spectrometry can verify identity and purity after storage or shipping.
Reconstitution begins with selecting a solvent that dissolves the peptide without causing degradation. Water or aqueous buffer is suitable for many hydrophilic sequences, while hydrophobic peptides may require a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before dilution. The solvent is added to the vial rather than the powder being scraped out, and the mixture is swirled or inverted gently to avoid foaming. Complete dissolution should be confirmed visually, and insoluble material may indicate aggregation or impurities. Because solvent tolerance varies, published solubility information or a small test dissolution can guide handling.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder or frozen solution | Powder typically more stable for long-term storage; solutions require colder conditions. |
| Recommended reconstitution solvent | Water, buffer, or water-miscible organic solvent | Matches peptide hydrophobicity; test small portion if unknown. |
| Typical working aliquot size | Single-use volumes in low-binding tubes | Reduces repeated warming and cooling and contamination risk. |
| Short-term shipping condition | Dry ice for frozen solutions; gel packs for powders | Insulation and temperature logging help document transit. |
| Common purity check | Reverse-phase HPLC with UV detection | Often paired with mass spectrometry for identity confirmation. |
Reconstitution is often performed with sterile water, buffer, or a water-miscible organic solvent, depending on solubility. The solvent should be added gently along the vial wall, and the solution mixed by gentle swirling rather than vigorous vortexing, which can cause foaming and surface denaturation. Some sequences require a small amount of base or acid to dissolve, followed by pH adjustment. Preparing a concentrated stock solution can simplify later dilution, but the stock itself may have limited stability. Records of solvent, concentration, and date support reproducibility.
After reconstitution, dividing the solution into single-use aliquots limits multiple warming and cooling events and reduces contamination risk. Low-binding polypropylene tubes are often preferred because peptides can adsorb to glass or untreated plastic surfaces. Filling headspace with nitrogen or argon can slow oxidation, and amber or foil-wrapped containers reduce photodegradation. Each aliquot should be labeled with peptide identity, concentration, date, and storage conditions. Frozen aliquots should be thawed quickly and kept on ice until use.
When a peptide arrives, the vial should be inspected for damage, and its label, lot number, and accompanying analytical data should be recorded. Cold vials should equilibrate to room temperature before opening to prevent condensation on the powder. Moisture uptake can reduce stability and complicate accurate weighing or reconstitution. Inventory systems that track date, quantity, and storage location help prevent unnecessary temperature cycling. Personnel should follow institutional or manufacturer instructions for any specific peptide.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
Temperature is a primary variable because most degradation reactions slow as thermal energy decreases. Lyophilized powders are commonly held at -20 °C for routine work and at -80 °C for longer archival periods, though exact recommendations depend on the peptide. Solutions are less stable than dry powders in many cases, and repeated freeze-thaw cycles can promote aggregation or precipitation. Inert atmospheres, such as argon or nitrogen, can limit oxidation for oxygen-sensitive sequences. Desiccants reduce water activity, which lowers hydrolysis rates during storage.
Light exposure can damage aromatic residues and certain labels, so amber vials or opaque containers are often used. pH control matters in solution, as extreme acidity or alkalinity accelerates backbone cleavage; buffers may also introduce ions that affect solubility. Microbial growth is a concern for aqueous preparations that lack preservatives, though many research peptides are handled in sterile or low-bioburden conditions. Container materials can adsorb peptides, particularly hydrophobic or positively charged sequences, reducing recovery. These factors interact, meaning storage decisions balance chemical stability, physical state, and intended use.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, and conformation. The amide backbone can hydrolyze under acidic or basic conditions, while side chains such as methionine, cysteine, and tryptophan are prone to oxidation. Aggregation may occur when hydrophobic regions associate, especially near surfaces or at high concentration. Because these pathways differ among peptides, no single storage condition applies to all sequences. Stability studies therefore examine each peptide under defined temperature, pH, and humidity ranges.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
Reconstitution solvent depends on peptide solubility and intended use; water, buffer, or small amounts of organic solvent may be needed. After dissolution, solutions are typically aliquoted into single-use portions to avoid repeated freeze-thaw cycles. Aliquots are stored at -20 °C or -80 °C, depending on stability. Labels include concentration, solvent, date, and operator. Sterile filtration may be used when microbial control is required, but filters can adsorb peptides. The optimal concentration and solvent are often determined empirically.
Cold-chain shipping uses insulated containers, phase-change packs, and temperature indicators. Dry ice maintains -70 °C or lower but requires venting to avoid pressure buildup. Gel packs provide 2-8 °C for shorter transit. Upon arrival, recipients should record temperature indicators and transfer vials promptly to storage. Deviations from specified conditions should be documented and may require analytical re-check. The effect of a brief temperature excursion is peptide-specific and not always predictable from general rules.
=== Genetics === sIBM is not inherited and is not passed on to the children of IBM patients. There are genetic features that do not directly cause IBM but that appear to predispose a person to getting IBM – having this particular combination of genes increases one's susceptibility to getting IBM. Some 67% of IBM patients have a particular combination of human leukocyte antigen genes in a section of the 8.1 ancestral haplotype in the center of the MHC class II region. sIBM is not passed on from generation to generation, although the susceptibility region of genes may be. There are also several rare forms of hereditary inclusion body myopathy that are linked to specific genetic defects and that are passed on from generation to generation. Since these forms do not show features of muscle inflammation, they are classified as myopathies rather than forms of myositis. Because they do not display inflammation as a primary symptom, they may in fact be similar, but different diseases to sporadic inclusion body myositis. There are several different types, each inherited in different ways. See hereditary inclusion body myopathy. A 2007 review concluded there is no indication that the genes responsible for the familial or hereditary conditions are involved in sIBM.
Dense irregular connective tissue is a form of dense connective tissue characterized by collagen fibers that appear randomly interwoven instead of forming parallel bundles as in dense regular connective tissue. Dense irregular connective tissue has less ground substance than loose connective tissue. Fibroblasts are the predominant cell type, scattered sparsely across the tissue.
structural formula A graphical representation of the molecular structure and geometry of a particular chemical compound, showing how the atoms are arranged in real, three-dimensional space. Chemical bonding within the molecule is also shown, either implicitly or explicitly. When known with certainty, structural formulas are very useful because they allow chemists to visualize the molecules and the structural changes that occur in them during chemical reactions.
Enzymes with a substituted-enzyme mechanism can exist in two states, E and a chemically modified form of the enzyme E*; this modified enzyme is known as an intermediate. In such mechanisms, substrate A binds, changes the enzyme to E* by, for example, transferring a chemical group to the active site, and is then released. Only after the first substrate is released can substrate B bind and react with the modified enzyme, regenerating the unmodified E form. When a set of v by [S] curves (fixed A, varying B) from an enzyme with a substituted-enzyme mechanism are plotted in a Lineweaver–Burk plot, a set of parallel lines will be produced. This is called a secondary plot. Enzymes with substituted-enzyme mechanisms include some oxidoreductases such as thioredoxin peroxidase, transferases such as acylneuraminate cytidylyltransferase and serine proteases such as trypsin and chymotrypsin. Serine proteases are a very common and diverse family of enzymes, including digestive enzymes (trypsin, chymotrypsin, and elastase), several enzymes of the blood clotting cascade, and many others. In these serine proteases, the E* intermediate is an acyl-enzyme species formed by the attack of an active site serine residue on a peptide bond in a protein substrate.
The first one to systematically expand and correct the chemical potentials of Bohr's atomic theory was Walther Kossel in 1914 and in 1916. Kossel explained that in the periodic table new elements would be created as electrons were added to the outer shell. In Kossel's paper, he writes: This leads to the conclusion that the electrons, which are added further, should be put into concentric rings or shells, on each of which ... only a certain number of electrons—namely, eight in our case—should be arranged. As soon as one ring or shell is completed, a new one has to be started for the next element; the number of electrons, which are most easily accessible, and lie at the outermost periphery, increases again from element to element and, therefore, in the formation of each new shell the chemical periodicity is repeated. In a 1919 paper, Irving Langmuir postulated the existence of "cells" which we now call orbitals, which could each only contain eight electrons each, and these were arranged in "equidistant layers" which we now call shells. He made an exception for the first shell to only contain two electrons. The chemist Charles Rugeley Bury suggested in 1921 that eight and eighteen electrons in a shell form stable configurations. Bury proposed that the electron configurations in transitional elements depended upon the valence electrons in their outer shell. He introduced the word transition to describe the elements now known as transition metals or transition elements.
Sources: en.wikipedia.org
=== Mental health and Dementia === Mental health conditions are common in people living with dementia. Depression and anxiety frequently occur alongside cognitive decline, and can worsen day‑to‑day functioning and quality of life. People with dementia who experience co‑morbid depression or anxiety are at increased risk of suicidal ideation, suicide attempts, and death by suicide, particularly in the earlier stages of dementia. Some groups appear to have an even higher likelihood of developing mood problems. For example, frontotemporal dementia is often associated with early behavioural and emotional changes, and people with young‑onset dementia (where symptoms begin before age 65) may be more vulnerable to depression and anxiety because of the impact on employment, identity, and family roles. Mental health conditions in people living with dementia are often under-recognised and undertreated. Untreated depression and anxiety can contribute to distress, behavioural changes, greater care needs and an increased risk of admission to long‑term care. However, it is not inevitable that people with dementia will experience mood problems. When symptoms occur, they can be assessed as for those living without dementia. Non‑drug approaches—such as psychological therapies, social engagement, and activity‑based interventions are recommended as first‑line treatments, with medication reserved for specific situations. Research also suggests that mental health difficulties earlier in life may be linked to later dementia risk.
=== Metastasis === CAF have been found to promote tumour metastasis in numerous ways. Firstly, they may alter gene expression and have been found to upregulate specific genes involved in pro-tumorigenic pathways including heat shock factor 1 (HSF1). They can also interfere with the function of tumour suppressor genes, such as Tumour protein p53, leading to higher rates of cell proliferation due to the loss of control of the cell cycle. Additionally, CAF have the ability to break down proteins in the extracellular matrix and basement membranes leading to disruption to the normal structure allowing cells to move away from their primary region. The group of proteins known as the matrix metalloproteinases are key to this process. CAF also direct the movement of neoplastic cells by using the Rho-dependent signaling pathway to create tracks for these cells in the matrix.
== See also == China–United States trade war Kondratiev wave CHIPS and Science Act European Chips Act Global Partnership on Artificial Intelligence Partnership on AI Pax Silica World Artificial Intelligence Cooperation Organization AI nationalism AI tiger
=== Veterinary medicine === DMSO is commonly used in veterinary medicine as a liniment for horses, alone or in combination with other ingredients. In the latter case, often, the intended function of the DMSO is as a solvent, to carry the other ingredients across the skin. Also in horses, DMSO is used intravenously, again alone or in combination with other drugs. It is used alone for the treatment of increased intracranial pressure and/or cerebral edema in horses.
Sources: en.wikipedia.org
These coping mechanisms that aim to preserve the sacred have been found by researchers to increase well-being and return the individual back to the sacred. Overall, spirituality is a process that occurs over a lifetime and includes searching, conserving, and redefining what is sacred in an extremely individualized manner. It does not always have a positive effect and in fact, has been associated with very negative events and life changes. Research is lacking in spirituality but it is necessary because spirituality can assist in enhancing the experiences of the uncontrollable parts of life.
The activity of tyrosine hydroxylase in the brains of patients with Alzheimer's disease has been shown to be significantly reduced compared to healthy individuals. Tyrosine hydroxylase is also an autoantigen in autoimmune polyendocrine syndrome (APS) type I. A consistent abnormality in Parkinson's disease is degeneration of dopaminergic neurons in the substantia nigra, leading to a reduction of striatal dopamine levels. As tyrosine hydroxylase catalyzes the formation of L-DOPA, the rate-limiting step in the biosynthesis of dopamine, tyrosine hydroxylase-deficiency does not cause Parkinson's disease, but typically gives rise to infantile parkinsonism, although the spectrum extends to a condition resembling dopamine-responsive dystonia. A direct pathogenetic role of tyrosine hydroxylase has also been suggested, as the enzyme is a source of H2O2 and other reactive oxygen species (ROS), and a target for radical-mediated injury. It has been demonstrated that L-DOPA is effectively oxidized by mammalian tyrosine hydroxylase, possibly contributing to the cytotoxic effects of L-DOPA. Like other cellular proteins, tyrosine hydroxylase is also a possible target for damaging alterations induced by ROS. This suggests that some of the oxidative damage to tyrosine hydroxylase could be generated by the tyrosine hydroxylase system itself. Tyrosine hydroxylase can be inhibited by the drug α-methyl-para-tyrosine (metirosine).
John Thomas Chain Jr. (December 11, 1934 – July 7, 2021) was a U.S. Air Force general. He was also a director of R. J. Reynolds Tobacco Company, ConAgra Foods, Inc., and Kemper Insurance Co., as well as holding other corporate offices.
Sources: en.wikipedia.org
Multiple freezing and thawing events can cause aggregation, precipitation, or loss of soluble peptide. Dividing a solution into single-use aliquots before freezing reduces this risk. If multiple cycles are unavoidable, stability should be checked after thawing.
Low-binding polypropylene tubes are often used because some peptides adsorb to glass or standard plastic. The choice depends on peptide hydrophobicity and charge. Containers should be clean, sterile when needed, and compatible with the solvent.
Reverse-phase chromatography can assess purity and retention time, while mass spectrometry confirms molecular mass. These methods can detect degradation products and sequence-related impurities. Results are compared with a reference sample or initial analysis.
Allow the sealed vial to reach room temperature before opening to reduce condensation. Use a suitable solvent and gentle mixing rather than vigorous agitation. Follow the supplier's solubility information when available.